Servier is an international and independent pharmaceutical company governed by a non-profit foundation. We have considerable expertise in the discovery, development and commercialization of therapeutics for diverse fields of medicine. Servier has a turnover of 4.176 billion euros in 2018, 25% of which (excluding generics) is reinvested in R&D. We employ 22000 people and our products are available in 149 countries. Corporate growth at Servier is driven by our continuous pursuit of innovation in five areas of excellence: cardiovascular and immune-inflammatory diseases, neuropsychiatric disorders, cancer and diabetes. We are a leading force in cardiology—number 2 in Europe, number 5 worldwide—and oncology has become a top priority in recent years; we also manufacture high-quality generic drugs. We have an active partnership policy in the field of biotechnology and we are investing in e-health through our internal WeHealth by Servier initiative.